Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Movement Disorders : Official Journal of the Movement Disorder Society|February 27, 2009
Cysteine elevation in levodopa-treated patients with Parkinson's diseaseThomas Müller, Wilfried KuhnClinical Neuropharmacology|September 25, 2023
Effects of Amantadine Sulfate on Motor Impairment and Execution of Motor Sequences in Patients With Parkinson DiseaseThomas Müller, Wilfried KuhnEuropean Journal of Clinical Pharmacology|June 8, 2006
Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patientsThomas Müller, Wilfried KuhnMovement Disorders : Official Journal of the Movement Disorder Society|May 9, 2009
Homocysteine levels after acute levodopa intake in patients with Parkinson's diseaseThomas Müller, Wilfried KuhnJournal of Neural Transmission (Vienna, Austria : 1996)|November 12, 2021
Complex motion series performance differs between previously untreated patients with Parkinson's disease and controlsThomas Müller, Wilfried KuhnArchives of Neurology|May 19, 2004
Levodopa-associated increase of homocysteine levels and sural axonal neurodegenerationThomas Müller, Kathrin Renger, Wilfried KuhnJournal of Neural Transmission (Vienna, Austria : 1996)|January 11, 2020
Kinesiology training in patients with Parkinson's disease: results of a pilot studyWilfried Kuhn, Tanja Neufeld, Thomas MüllerExpert Review of Clinical Pharmacology|February 2, 2023
Aminoadamantanes: from treatment of Parkinson's and Alzheimer's disease to symptom amelioration of long COVID-19 syndrome?Thomas Müller, Peter Riederer, Wilfried KuhnClinical Neuropharmacology|December 13, 2005
Levodopa intake increases plasma levels of S-adenosylmethionine in treated patients with Parkinson diseaseThomas Müller, Brian Fowler, Wilfried KuhnDegenerative Neurological and Neuromuscular Disease|October 3, 2022
No Vitamin D Deficiency in Patients with Parkinson's DiseaseWilfried Kuhn, Georg Karp, Thomas MüllerPageof 3